08045800513
Send Inquiry
Send InquiryGlimperide, Metformin & Pioglitazone Combination (Extended Release)
MOQ : 15-30 Boxes
Glimperide, Metformin & Pioglitazone Combination (Extended Release) Specification
- Drug Type
- Specific Drug
- Ingredients
- Glimepride 2 mg + Pioglitazone 30 mg (SR)
- Physical Form
- Tablets
- Function
- Other
- Recommended For
- Management of Type 2 diabetes (NIDDM)
Glimperide, Metformin & Pioglitazone Combination (Extended Release) Trade Information
- Minimum Order Quantity
- 15-30 Boxes
- Payment Terms
- Western Union, Cash in Advance (CID), Cheque, Cash Advance (CA)
- Sample Policy
- Sample costs shipping and taxes has to be paid by the buyer
- Packaging Details
- ALu-Alu,10*10 Pack
- Main Domestic Market
- All India
- Certifications
- WHO-GMP
About Glimperide, Metformin & Pioglitazone Combination (Extended Release)
Glimperide, Metformin & Pioglitazone Combination (Extended Release) Tablets are specifically designed for effective management of Type 2 Diabetes Mellitus (NIDDM). Available in two formulations - Glimepiride 1 mg + Metformin 500 mg + Pioglitazone 15 mg (ER) and Glimepiride 2 mg + Metformin 500 mg + Pioglitazone 15 mg (ER) - these tablets combine three active ingredients that work synergistically to help control blood sugar levels in adults and older individuals. Glimepiride stimulates the pancreas to produce insulin, Metformin decreases glucose production in the liver, and Pioglitazone improves insulin sensitivity. The extended-release formulation ensures a sustained effect throughout the day for better glycemic control. These tablets are recommended for diabetic patients seeking reliable and comprehensive management of their condition.
FAQs of Glimperide, Metformin & Pioglitazone Combination (Extended Release):
Q: What is the primary use of this medication?
A: It is used for the management of Type 2 Diabetes Mellitus (NIDDM).Q: What are the active ingredients in this product?
A: The tablets contain Glimepiride, Metformin, and Pioglitazone in specified doses.Q: Who is suitable to use these tablets?
A: These tablets are suitable for adults and elderly individuals diagnosed with Type 2 Diabetes.Q: Why is it an extended-release formulation?
A: The extended-release formulation ensures sustained blood sugar control over a longer period.Q: Are these tablets designed for monotherapy or combination therapy?
A: These tablets are intended for combination therapy to address diabetes from multiple pathways.
Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
More Products in Diabetic Tablets Category
Epalrestat 50 mg
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Physical Form : Tablets
Function : Other
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Diabetic Neuropathy
Metformin-500 mg, Glibenclamide 5 mg & Pioglitazone 15 mg
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Physical Form : Tablets
Function : Other
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : 3rd line treatment for Type 2 Diabetes Mellitus, when all other treatment fails
Calcium Dobisilate 500 mg
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Physical Form : Tablets
Function : Other
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Diabetic retinopathy and Glaucoma,Diabetic Microangiopathy
Glimperide & Metformin Combinations
Minimum Order Quantity : 1530 Boxes
Drug Type : Specific Drug
Physical Form : Tablets
Function : Other
Ingredients : Glimepride 2 mg + Pioglitazone 30 mg (SR)
Recommended For : Management of Type 2 diabetes (NIDDM)
Contact Details
- Call us-9877184734, 6283732271, Plot No. 364, Industrial Area, Phase-1,Chandigarh - 160002, India
- Phone : 08045800513
GST : 04AAHCS5485R1ZJ
- Mr Sanjeev Kumar Sethi (Managing Director)
- Mobile : 08045800513
- cmd@solitairegroup.in
- Mobile :+919815777744
SOLITAIRE PHARMACIA PVT. LTD.
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
